Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shin Tsunekawa

Showing results (61-70 of 62) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 62 results.
Diabetology International|January 24, 2024
The efficacy of switching basal-bolus insulin therapy to basal insulin-supported oral therapy with a glinide and an α-glucosidase inhibitor in patients with type 2 diabetes depends on insulin secretory capacity, but not on blood glucose profiles and insulin dosages prior to the switchingToshihito Ando, Masaki Kondo, Yuriko Asada-Yamada, et al.
The Journal of Clinical Investigation|July 30, 2019
TDP-43 regulates early-phase insulin secretion via CaV1.2-mediated exocytosis in isletsKunihiko Araki, Amane Araki, Daiyu Honda, et al.
Pageof 7

Showing results (61-70 of 62) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 62 results.
Diabetology International|January 24, 2024
The efficacy of switching basal-bolus insulin therapy to basal insulin-supported oral therapy with a glinide and an α-glucosidase inhibitor in patients with type 2 diabetes depends on insulin secretory capacity, but not on blood glucose profiles and insulin dosages prior to the switchingToshihito Ando, Masaki Kondo, Yuriko Asada-Yamada, et al.
The Journal of Clinical Investigation|July 30, 2019
TDP-43 regulates early-phase insulin secretion via CaV1.2-mediated exocytosis in isletsKunihiko Araki, Amane Araki, Daiyu Honda, et al.
Pageof 7